The HIV / AIDS crisis bears a number of clinical and practical similarities to the new challenge of producing drugs to treating chronic disease in lower-income countries, providing a useful case study when determining effective strategies. A new literature review by Philip Stevens, the second in a three-part series, examines what can be learned from the global response to HIV / AIDS – and reveals some costly mistakes that should not be repeated.

Counterfeit and substandard medicines are still harming the reputation of the Indian pharmaceutical industry and endangering the wellbeing of patients, according to a recent survey.

Chronic conditions such as diabetes, cancers and heart disease are gradually displacing infectious diseases as the greatest health problem in lower-income countries. The HIV / AIDS crisis bears a number of clinical and practical similarities to this new challenge, providing a useful case study when determining effective strategies. A new literature review by Philip Stevens, the first in a three-part series, examines what can be learned from the global response to HIV / AIDS – and reveals some costly mistakes that should not be repeated.

A global study on import tariffs on medicines